SCHEMBL4538140

SCHEMBL4538140

COc1ccc(SC(C(=O)NO)c2ccccc2)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.57
MAPT P10636 4/20 0.57
NPSR1 Q6W5P4 2/20 0.57
ALDH1A1 P00352 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
TDP1 Q9NUW8 2/20 0.56
HTT P42858 1/20 0.54
ADAM17 P78536 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.47
PKM P14618 1/20 0.47
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
PCTP Q9UKL6 1/20 0.44
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PAX8 Q06710 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4534294 0.82 ADAM17 (0.66) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL4532011 0.82 MAPT (0.60) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL4526704 0.80 MAPT (0.56) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL4536275 0.80 LMNA (0.54) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL4537378 0.80 MAPT (0.61) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL2839882 0.79 ADAM17 (0.55) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL6819753 0.79 PDE4A (0.57) NPSR1ALDH1A1TDP1L3MBTL1PDE4A
SCHEMBL8202619 0.78 ADAM17 (0.43) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL2846675 0.78 LMNA (0.72) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL8119311 0.77 LMNA (0.62) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 LMNA 424/4885MAPT 1533/4885NPSR1 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.